866-997-4948(US-Canada Toll Free)

Natural Killer Cells - Competitive Landscape, Technology and Pipeline Analysis, 2016

Published By :

DelveInsight

Published Date : Jul 2016

Category :

Oncology

No. of Pages : 155 Pages

DelveInsights, Natural Killer Cells- Competitive Landscape, Technology and Pipeline Analysis, 2016, report provides comprehensive insights about pipeline drugs across this indication. Key objective of the report is to establish the understanding for all the pipeline drugs that fall under Natural Killer Cells.
This report provides information on the therapeutic development based on the Natural Killer Cells dealing with all the pipeline drugs, comparative analysis of Natural Killer Cellsat various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companys information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

Note: This report will be delivered to the client in 48 hours

Reports Highlights

Natural killer cell Therapy Pipeline scenario
Collaborations & partnering deals
Current Prominent Research Areas and Key Players
Pipeline product profiles Natural killer cell Technologies and Targeted Antigens
Licensing opportunities
Market Drivers and Barriers

Table of Contents

1 Executive Summary Snapshot Report
2 Executive Summary
3 Natural Killer Cells Overview
4 Analysis of NK cells receptors
NK cells receptors and shares
CAR-expressing NK-92 associated targets and Indications
Targets of NK cells and Analysis
Pipeline products under development by the company
NK Cells Therapy Collaborations and Deal Year
NK Cells Therapy Collaborations and Deal value
Companies Licensing Agreement for NK cells
Financing details of NK cells
Companies received Grants for NK cells
Designation
Institutes involved in NK cells
NK cells Technologies
Clinical trials & Completion Year
Phase III Drugs
Phase II Drugs
Phase I Drugs
Recent Trends in NK Cells Therapy
Leading Companies and their shares in Natural Killer cells Therapy
Market Drivers
Market Barriers
5 SWOT Analysis
6 Pipeline Therapeutics
7 Therapeutics under Development by Companies
8 Last Stage Products (Phase III)
Comparative Analysis
10 Mid Stage Products (Phase II)
Comparative Analysis
19 Early Stage Products (Phase I)
Comparative Analysis
42 Pre-Clinical and Discovery Products
Comparative Analysis
50 Therapeutic Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Assessment by Stage and Molecule Type
51 Appendix
52 DelveInsight Consulting Services
53 About DelveInsight
54 Contact Us
55 Disclaimer
List of Tables

Table 1: Natural Killer Cells -Target Antigens and Companies
Table 2: Collaboration and Deal Values for NK cell therapy, 2016
Table 3: Companies of NK cells Licensing Agreement for future developments, 2016
Table 4: Natural Killer Cell -Trial Completion Year, Phase, Drug and Company
Table 5:Number of Products Under Development for Natural Killer Cells,2016
Table 6: Number of Products under Development by Companies, 2016
Table 7: Last Stage Products (Phase III and Filed), 2016
Table 8: Mid Stage Products (Phase II),2016
Table 9: Early Stage Products (Phase I), 2016
Table 10: Pre-Clinical and Discovery Products, 2016
Table 11: Assessment by Monotherapy Products, 2016
Table 12:Assessment by Combination Products, 2016
Table 13: Assessment by Route Of Administration, 2016
Table 14:Assessment by Stage and Route Of Administration, 2016
Table 15: Assessment by Molecule Type, 2016
Table 16: Assessment by Stage and Molecule Type, 2016
Table 17: Assessment by Stage of development and Domain, 2016

List of Figures

Figure 1: Receptors of NK Cell and share of products, 2016
Figure 2: Target of NK cells and share of products, 2016
Figure 3: : Natural Killer Cell -Number of Products (N) and Stages Of Development
Figure 4: Collaboration and deal value, 2016
Figure 5:NK Cells designation and Number of Products, 2016
Figure 6:NK Cells technologies with their companies, 2016
Figure 7: Natural Killer Cell-Study Completion Date, Indication and Recruitment status of Phase III Drugs, 2016
Figure 8: Natural Killer Cell-Study Completion Date, Indication and Recruitment status of Phase II Drugs, 2016
Figure 9: Natur+M33al Killer Cell-Number of Trials (N) and Study Completion Year
Figure 10: Leading NK Cells companies and their shares, 2016
Figure 11: Number of Products under Development for Natural Killer Cells, 2016
Figure 12:Last Stage Products (Phase III), 2016
Figure 13: Mid Stage Products (Phase II), 2016
Figure 14: Early Stage Products (Phase I), 2016
Figure 15:Pre-Clinical and Discovery Products, 2016
Figure 16: Assessment by Monotherapy Products, 2016
Figure 17: Assessment by Combination Products, 2016
Figure 18: Assessment by Route of Administration, 2016
Figure 19: Assessment by Stage and Route of Administration, 2016
Figure 20: Assessment by Molecule Type, 2016
Figure 21: Assessment by Stage and Molecule Type, 2016
Figure 22: Assessment by Stage and Domain, 2016

List of Table

NA

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *